DDInter364 DDInter462
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, deb
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
Chlorpropamide {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dabrafenib
Chlorpropamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dabrafenib
Chlorpropamide {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) regulates {v} (Gene) ERBB2
ERBB2 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Chlorpropamide {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) covaries with {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dabrafenib
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} (Compound) causes {v} (Side Effect) Abdominal pain
Abdominal pain {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Chlorpropamide {u} (Compound) resembles {v} (Compound) Sulfacetamide
Sulfacetamide {u} (Compound) resembles {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dabrafenib
Chlorpropamide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Chlorpropamide (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Dabrafenib (Compound)
Chlorpropamide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Chlorpropamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Chlorpropamide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) regulates ERBB2 (Gene) and ERBB2 (Gene) is upregulated by Dabrafenib (Compound)
Chlorpropamide (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) covaries with HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Dabrafenib (Compound)
Chlorpropamide (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Chlorpropamide (Compound) resembles Glimepiride (Compound) and Glimepiride (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Chlorpropamide (Compound) resembles Glipizide (Compound) and Glipizide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Chlorpropamide (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib